Loss of Forkhead Box O3 Facilitates Inflammatory Colon Cancer: Transcriptome Profiling of the Immune Landscape and Novel Targets

Harrison M. Penrose,1 Chloe Cable,1 Sandra Heller,1 Nathan Ungerleider,1 Hani Nakhoul,1 Melody Baddoo,1 Alifiani B. Hartono,1 Sean B. Lee,1 Matthew E. Burow,2 Erik F. Flemington,1 Susan E. Crawford,3 and Suzana D. Savkovic1

1Department of Pathology and Laboratory Medicine, Tulane University, New Orleans, Louisiana; 2Department of Medicine, Section of Hematology and Medical Oncology, Tulane University Health Sciences Center, New Orleans, Louisiana; and 3Department of Surgery, NorthShore University Research Institute, Affiliate of University of Chicago Pritzker School of Medicine, Evanston, Illinois

SUMMARY
Loss of FOXO3 transcription function, associated with human IBD and colon cancer progression, facilitates inflammatory colon cancer in mice. Transcriptome profiling of FOXO3 deficient colon and tumors revealed an immune landscape, molecular pathways, and novel transcripts similarly dysregulated in IBD and colon cancer.

BACKGROUND & AIMS: Diminished forkhead box O3 (FOXO3) function drives inflammation and cancer growth; however, mechanisms fostering these pathobiologies are unclear. Here, we aimed to identify in colon loss of FOXO3-dependent cellular and molecular changes that facilitate inflammation-mediated tumor growth.

METHODS: FOXO3 knockout (KO) and wild-type (WT) mice were used in the AOM/DSS model of inflammation-mediated colon cancer. Bioinformatics were used for profiling of mRNA sequencing data from human and mouse colon and tumors; specific targets were validated in human colon cancer cells (shFOXO3).

RESULTS: In mice, FOXO3 deficiency led to significantly elevated colonic tumor burden (incidence and size) compared with WT ($P < .05$). In FOXO3 KO colon, activated molecular pathways overlapped with those associated with mouse and human colonic inflammation and cancer, especially human colonic tumors with inflammatory microsatellite instability (false discovery rate $< 0.05$). FOXO3 KO colon, similar to tumors, had increased neutrophils, macrophages, B cells, T cells, and decreased natural killer cells (false discovery rate $< 0.05$). Moreover, in KO colon differentially expressed transcripts were linked to activation of inflammatory nuclear factor kappa B, tumorigenic cMyc, and bacterial Toll-like receptor signaling. Among differentially expressed transcripts, we validated altered expression of integrin subunit alpha 2 (ITGA2), ADAM metallopeptidase with thrombospondin type 1 motif 12, and ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 5 in mouse WT and FOXO3 KO colon and tumors ($P < .05$). Similarly, their altered expression was found in human inflammatory bowel disease and colon cancer tissues and linked to poor patient survival. Ultimately, in human colon cancer cells, FOXO3 knockdown (shFOXO3) led to significantly increased ITGA2, and silencing ITGA2 (siRNA) alone diminished cell growth.
CONCLUSIONS: We identified the loss of FOXO3-mediated immune landscape, pathways, and transcripts that could serve as biomarkers and new targets for inflammatory colon cancer treatment. (Cell Mol Gastroenterol Hepatol 2019;7:391-408; https://doi.org/10.1016/j.jcmgh.2018.10.003)

Keywords: Colon Cancer; Inflammation; FOXO3; RNAseq.

See editorial on page 295.

Colon cancer, the second leading cause of cancer-related death in the United States, is driven by alterations in the tissue microenvironment caused by obesity, imbalances in the microbiome, and inflammation. Local, chronic inflammation of the colon, as observed in inflammatory bowel disease (IBD), is associated with increased risk of cancer development and progression. The inflammatory microenvironment initiates and fosters cancer progression as evident by its ability to stimulate transformed cell proliferation, survival, angiogenesis, metastasis, and resistance to chemotherapy. Dynamic communication among cancer cells and the inflammatory microenvironment favors immune cell infiltration and the release of cytokines and growth mediators, both facilitators of cancer progression. Furthermore, inflammation generated reactive nitrogen and oxidative species have been shown to mediate genetic instability in cancer cells. In the colon, inflammation-mediated genetic microsatellite instability (MSI) favors an increased mutation rate leading to cancer progression. However, the nature of the immune cell types, inflammatory mediators, and transcriptional programs that drive inflammation-mediated colon cancer are neither fully examined nor understood.

Transcription factor FOXO3, a member of the forkhead box O (FOXO) family, plays critical roles in diverse cellular functions including proliferation, apoptosis, and metabolism. In immune cells, FOXO3 activity is critical for maintenance of immune progenitor cell homeostasis, and its deficiency in B and T cells leads to their enhanced activity during infection. In patients with inflammatory diseases such as rheumatoid arthritis and IBD, genome-wide association studies have shown that individuals with a single nucleotide polymorphism (SNP) in the FOXO3 gene locus leading to lower FOXO3 expression have a more aggressive disease course. Moreover, in human colon cancer tissues loss of FOXO3 transcription activity is associated with tumor growth. Previously, we demonstrated that mice deficient in FOXO3 have increased susceptibility to colonic inflammation and elevated rates of cell proliferation. Thus, we hypothesized that FOXO3’s immunosuppressive and tumor-suppressive functions might intersect to drive inflammation-mediated colon cancer. Here, we aimed to determine loss of FOXO3-dependent changes in the immune landscape, molecular pathways, and downstream transcripts involved in disease pathobiology.

We demonstrated that in a mouse model of inflammation-mediated colon cancer FOXO3 deficiency led to increased tumor burden, an altered immune cell landscape, activated molecular pathways, and transcriptional programs associated with inflammation and tumor growth. Our analysis identified FOXO3-dependent transcripts that could potentially serve as biomarkers and prospective new targets for treatment.

Materials and Methods

Animals

Wild-type (WT) and FOXO3 knockout (FOXO3 KO) mice on a C57BL/6 genetic background were housed at the Tulane University School of Medicine, a pathogen-free facility in static, microisolator caging. Homozygous littermates were offspring of heterozygous breeders and genotyped as described by Lin et al. All experiments were completed according to guidelines and procedures determined by the Tulane Institutional Animal Care and Use Committee.

Azoxymethane and Dextran Sulfate Sodium Treatment

Mice, 6–8 weeks old, were injected intraperitoneally with a single dose (10 mg/kg) of azoxymethane (AOM) (Sigma-Aldrich, St Louis, MO; A5486) and subsequently administered 3 cycles of 2.5% dextran sulfate sodium (DSS) (MP Biomedicals, Santa Ana, CA; 160110) in drinking water for 5 days with 3-week intervals between each treatment regimen. After 8 weeks of recovery, mice were killed, and colonic tissues were collected for analysis. Tumor counts and measurements were conducted in a blinded fashion.

Cell Culture and Generation of Short Hairpin RNA Stable Cell Lines

Human colon cancer HCT116 cells (ATCC) were grown in complete McCoy’s 5A medium (Corning, Corning, NY; 10050CV) supplemented with 10% fetal bovine serum (Gibco Laboratories, Gaithersburg, MD; A3160602). For generating stable short hairpin RNA (shRNA) knockdown cell lines, FOXO3-specific shRNA (shFOXO3) and control shRNA were cloned into the TET-ON all in one LT3GEPIR vector by using the following nucleotide shRNA guide sequences: 5′–CATGTTCATGGGAGCTTGA–3′ (shFOXO3), 5′–CATGTTCATGGGAGCTTGA–3′ (shFOXO3),...
5'-TAGATAAGCATTATAATTCCTA-3' (shCon). Sequence verified plasmids were transfected into HCT116 cells by using lipofectamine 3000 according to manufacturer’s instructions (Invitrogen, Carlsbad, CA; L3000001). Stable cell lines were generated from single cells by using puromycin selection (250 ng/mL; Sigma-Aldrich; P8833), and doxycycline-inducible (2 μg/mL; Sigma-Aldrich; D9891) knockdown of FOXO3 was validated by quantitative polymerase chain reaction (qPCR) and immunoblot.

Small Interfering RNA

Human colon cancer HCT116 cells were transfected with integrin subunit alpha 2 (ITGA2) specific pooled small interfering RNA (Sigma-Aldrich; EH040531) or equal amounts of negative-control scramble oligonucleotides using lipofectamine 3000 according to manufacturer’s instructions (Invitrogen; L3000001). Efficiency of the knockdown was validated by qPCR and immunoblot.

Protein Extraction and Immunoblotting

Experimental cells were used for protein extraction, and immunoblot was performed as described previously. The following specific antibodies against proteins were used: FOXO3 (Cell Signaling Technology, Danvers, MA; cat 2497, lot 8), ADAM metallopeptidase with thrombospondin type 1 motif 12 (ADAMTS12) (Abcam, Cambridge, United Kingdom; cat 203012, lot GR2390174; Thermo Scientific, Waltham, MA; cat PA568084, lot SK2479822E), ITGA2 (Abcam; cat 133557, lot GR19622312), ST8 alpha-N-acetyl-neuraminide alpha-2,6-sialyltransferase 5 (ST8SIA5) (Abcam; cat 184778, lot GR2231323), and β-actin (Cell Signaling Technology; cat 3700, lot 8). Proteins were visualized with IRDye-conjugated secondary antibodies (LI-COR Biotechnology, Lincoln, NE; goat anti-mouse, cat 92532210, lot C6072602; goat anti-rabbit, cat 92568071, lot 92632210) using the Odyssey infrared imaging system (LI-COR Biotechnology).

Cell Proliferation Assays

Human colon cancer HCT116 cells were plated on 96-well plates at a density of 5000 cells per well. After 72 hours, a portion of cell medium was removed, and MTS solution (Promega, Madison, WI; M3001) was added for 1 hour and incubated at 37°C. MTS-converted formazan product was detected in cell medium solution at 490 nm by using a Microplate Reader FLUOstar Optima (BMG Labtech, Ortenberg, Germany). Cell proliferation was calculated as a percentage of the mouse reference haploid genome sequence (Genome facilities/cancer-crusaders). RNAseq reads were mapped to the mouse reference haploid genome sequence (Genome Reference Consortium murine genome build 38, GRChm38). Subsequent identification of differentially expressed (DE) transcripts at the whole gene level between biological conditions was performed by using the software package RSEM (v1.2.25). Subsequent identification of differentially expressed (DE) transcripts at the whole gene level between biological conditions was performed by using EBseq and attained with a false discovery rate (FDR) of 0.05. Sequencing data along with the study design have been submitted in NCBI’s Sequence Read Archive and are available under study accession number SRP158292.
Transcriptome and Pathway Analysis

Networks, functional analysis, and interpretation of RNAseq data were performed by using Ingenuity Pathway Analysis (IPA) (Qiagen Inc). Transcripts entered into IPA met an expression threshold of >|1.5|-fold change with respect to control and an FDR <0.05. Transcriptional signatures from our samples were compared against available gene expression data from mouse colon with inflammation or dysplasia as well as human IBD and colon cancer samples using NCBI’s GEO2R after adjustment with Benjamini and Hochberg testing ($P < .05$). In addition, our transcriptional signatures were compared against
transcriptomes from human colon cancer tissue (The Cancer Genome Atlas [TCGA]) by using Firebrowse.\textsuperscript{23}

cBioPortal for Cancer Genomics

Investigation of transcript dysregulation in human colon cancer samples was analyzed by using the cBioPortal for Human Cancer Genomics\textsuperscript{24,25} (www.cbioportal.org). Selected genes in human colorectal adenocarcinoma patient samples (TCGA COAD) were analyzed by using RSEM (RNAseq by Expectation Maximization)\textsuperscript{26}; Case Set: All Tumors (631 patients/636 samples).

Cell-type Identification by Estimating Relative Subsets of RNA Transcripts

To identify the immune cell landscape in a mixed colonic tissue sample, the computational cell-type identification by estimating relative subsets of RNA transcripts (CIBERSORT) method was applied to RNAseq data.\textsuperscript{27} Mixture files were created by using transcripts per million (TPM) from RNAseq samples according to the CIBERSORT formatting requirements (http://cibersort.stanford.edu). For mouse immune and colonic cells, a custom gene signature, reference, and phenotype file were created in accordance with CIBERSORT format specifications using the following RNAseq run accession numbers: B cells (SRR1976588, SRR1976593, SRR3932662, SRR3932664), CD4 T cells (SRR1976591, SRR3932665), CD8 T cells (SRR3001784, SRR3001786, SRR3001782), macrophages (SRR1976597, SRR3932663, SRR2927689), neutrophils (SRR1177062, SRR1177063, SRR3932667, SRR1976571), natural killer (NK) cells (SRR1976589, SRR3932669, SRR1976596, SRR3932670), and colonocytes (SRR3189717 [ATCC CMT-93 cells], SRR3189714 [1638NT1 cells]). Only those values meeting a significance threshold of \( P < .05 \) were included in analysis.

Tumor Immune Estimation Resource

Tumor immune estimation resource (TIMER) was used to assess mRNA expression in human cancer relative to normal matched tissue (RNAseq RSEM, TCGA)\textsuperscript{28} (https://cistrome.shinyapps.io/timer/).

Gene Set Enrichment Analysis

Gene set enrichment analysis (GSEA) software and the Molecular Signature Database were used to determine activation of transcription factor targets from RNAseq data.\textsuperscript{29}

Histologic Analysis

Mouse tissue processing and immunohistostaining were performed by the Pathology Core Laboratory at Tulane University Health Sciences Center (http://medicine.tulane.edu/departments/patholgylaboratorymedicine/research/histology-laboratory) as described previously.\textsuperscript{19,20} Heat-induced epitope retrieval was performed on tissue sections by using Rodent Decloaker solution (BioCare Medical, Concord, CA; RD913) and cooked in an oster steamer for 40 minutes. Sections were blocked by using Rodent Block M (BioCare Medical; RBM961), followed by incubation with the following antibodies: ADAMTS12 (Abcam; cat 203012, lot GR2390174), ITGA2 (Abcam; cat 133557, lot GR19622312), ST8SIA5 (Abcam; cat 184777, lot GR2231323), and Ki67 (1:100, 45 minutes; BioCare Medical; CRM325). After washing, tissue sections were incubated with Rabbit-on-Rodent HRP-Polymer secondary (BioCare Medical; RMR622); sections were then washed and treated with Betazoid DAB chromogen (Biocare Medical; BDB2004), followed by counterstaining with Cat hematoxylin (Biocare Medical; CATHEM). Slides were dried in the oven, placed in xylene, and coverslipped (Acrymount; StatLab, McKinney, TX; SL804). Images were obtained by using the slide scanner Aperio CS2 (Leica, Wetzlar, Germany) and Image Scope software.

Statistical Analysis

All data are means ± standard deviation for a series of experiments. Statistical analysis was performed by Student unpaired \( t \) test or one-way analysis of variance and Student-Newman-Keuls post-test by using Graph Pad Instat 3 software (Graphpad Software, San Diego, CA). A \( P \) value <.05 was considered significant.

Results

In Mouse Colon, Forkhead Box O3 Deficiency Leads to Increased Tumor Burden and Activates Pathways Associated With Inflammation and Cancer

Because reduced FOXO3 transcription function has been linked to severity of human IBD and colon cancer pathobiology,\textsuperscript{12,13} we assessed how loss of its activity might contribute to inflammation-mediated colon tumor

Figure 1. (See previous page). In human IBD and cancer, FOXO3 mRNA levels are reduced and associated with poor survival and partial PI3K activating mutations. (A) In human IBD tissue samples, relative expression (microarray) of FOXO3 transcript was significantly reduced compared with normal matched control tissue (GSE4183, n = 23; Affymetrix probe ID: 204131_s_at; \( P < .05 \), IBD compared with normal colon, Student \( t \) test). (B) mRNA expression (RNAseq, RSEM) of FOXO3 across TCGA cohorts (TIMER, https://cistrome.shinyapps.io/timer/). (C) Representative Kaplan-Meier survival plot demonstrating decreased FOXO3 mRNA expression is associated with reduced colon cancer patient survival (GSE16125, n = 32; https://pre cog.stanford.edu/index.php). (D) PRECOG meta-z analysis indicating increased FOXO3 expression as prognostic for favorable overall cancer survival (\( P < .05 \), https://pre cog.stanford.edu/index.php). (E) In human colon cancer (TCGA), the 10 patients expressing the lowest FOXO3 mRNA (compared with average FOXO3 level in tumor) (RNAseq, HTseq) and their 3 (p.H1047R, p.H1048R, p.R88Q) corresponding PI3K activating mutations (MuTect2 Variant Browser) (UCSC Xena Genome Browser, http://xena.ucsc.edu).
progression. Initially, analysis of transcriptomes from patients with IBD (microarray) and colon cancer tissues (microarray and RNAseq) revealed decreased FOXO3 expression across both pathologies (Figure 1A and B). Compared with matched normal tissue, FOXO3 transcript levels were also decreased in approximately 60% of other cancers (TCGA) (Figure 1B). In addition, reduced FOXO3 in human colon cancer was linked to poor patient survival as assessed by KM estimate (Figure 1C), which was further supported by pan-cancer meta-z analysis demonstrating increased FOXO3 expression as a favorable prognostic indicator in cancer survival (Stanford, prediction of clinical outcomes from genomic profiles [PRECOG]) (Figure 1D). Last, we determined in human colon cancer tissues (TCGA) whether low FOXO3 expression was associated with increased PI3K activity, which is known to negatively regulate FOXO3 and favor cancer progression. In patients with the lowest FOXO3 transcript levels, 3 of 10 had PI3K activating mutations (UCSC, XENA) (Figure 1E), suggesting that in human colon cancer loss of FOXO3-

**Figure 1.** Changes in FOXO3 expression and function in IBD and cancer. (A) Diagram of FOXO3 sequence and protein. (B) Western blot analysis of FOXO3 levels in human colon cancer cell lines. (C) Heat map of FOXO3 transcript expression in colon cancer tissues. (D) Box plot of FOXO3 expression levels in colon cancer tissues. (E) Flow chart of FOXO3 signaling pathways in colon cancer. (F) Bar graph of FOXO3 activity in colon cancer tissues.

**Figure 2.** In mouse colon FOXO3 deficiency increases colonic tumor burden and activation of inflammatory and tumorigenic transcriptional programs. (A and B) Gross histology of WT and FOXO3 KO colonic tumors in the AOM/DSS mouse model. Colonic tumor incidence, size, and tumor burden were determined between WT and FOXO3 KO (n = 6 per experimental group, representative graph from 2 independent experiments; *P < .05 compared with WT, Student t test). (C) Venn diagrams depict the number of transcripts commonly or uniquely expressed in mouse FOXO3 KO colon and tumors (WT or KO in AOM/DSS model) relative to WT (n = 3 per experimental group, FDR < 0.05, EBseq). (D) Disease and function analysis of colonic FOXO3 KO transcriptome revealed association with inflammatory and cancer pathobiology (n = 3 per experimental group, FDR < 0.05, IPA). (E) Top canonical pathways activated in mouse FOXO3 KO colon (n = 6) compared with both mouse inflamed and dysplastic colonic tissue (GSE31106, n = 15) (FDR < 0.05, IPA).
mediated progression could be either PI3K-dependent or -independent. Together, these findings demonstrate that in human IBD and colon cancer, FOXO3 expression is reduced, in part, independently of upstream PI3K and associated with reduced patient survival.

By using KO mice, we assessed the loss of FOXO3-dependent transcriptional consequences that could facilitate inflammation-mediated cancer progression. In the AOM/DSS model, approximately one-third of FOXO3 KO mice displayed rectal prolapse; nevertheless, survival rates between WT and KO mice did not differ during the time of the experiment. Macroscopic examination of colon revealed that FOXO3 KO mice had a greater tumor incidence (2-fold) and size (>3 mm), leading to a significantly increased tumor burden (3-fold) compared with WT (Figure 2A and B). Microscopic assessment of tumors (H&E stained) for penetration of surrounding lamina propria or spreading to lymph nodes did not show differences between WT and FOXO3 KO, suggesting that in this model and for the duration of the experiment, cancer invasion and metastasis appear to be independent of FOXO3 deficiency. Next, RNAseq analysis showed in FOXO3 KO colon a significant number of DE transcripts were also shared with tumors (WT and FOXO3 KO) (Figure 2C). IPA of these DE transcripts indicated altered biological functions pertaining to tumor growth including increased cell migration, proliferation, angiogenesis, inflammation, cancer, and decreased apoptosis (Figure 2D). Moreover, the FOXO3 KO transcriptional signature displayed strong similarities with inflammatory and dysplastic transcriptomes of mouse colon (GSE31106) (Figure 2E), suggesting its functional deficiency might support both processes. Also, we found in FOXO3 KO colon that dysregulated pathways substantially overlapped with those altered in human IBD and colon cancer (GSE4183) (Figure 3). Particularly in KO colon and AOM/DSS tumors, IPA revealed gene expression was similar to transcriptomes from human colon cancers with MSI, characterized by an inflammatory tumor microenvironment (TCGA) (Figure 3B). These findings demonstrate that in mouse colonic tissue, FOXO3 deficiency increases tumor burden and promotes transcriptional changes similar to those occurring in human IBD and colon cancer, especially tumors with inflammatory MSI features.

**In Mouse Colon, Forkhead Box O3 Deficiency Leads to an Altered Immune Cell Landscape Similar to Inflammatory Tumors**

On the basis of the above findings and because loss of FOXO3 function is critical in mediating inflammatory and proliferative responses in both colonic and immune cells,9,14,15 we applied CIBERSORT27 to assess the relative abundance of immune cell types in experimental tissues. This program uses transcriptional signatures of distinct immune cell types to assess their presence in a mixed cell tissue by using RNAseq data.27 Compared with WT mice, FOXO3 KO colon showed significantly increased levels of macrophages (2-fold), neutrophils (3-fold), and reduced NK cells (Figure 4A). Also, although both B cells and T cells (CD4 and CD8) were elevated in FOXO3 KO colon, only increases in B cells (3-fold) reached statistical significance (Figure 4B). This immune profile, similarly described in human inflammatory colon cancer,3,32 was also seen in mouse AOM/DSS tumors (data not shown). Moreover, these findings were further supported by analysis of upstream pathways (IPA), which identified increased expression and activation of receptors and cytokines specific for the presence of macrophages (interleukin 1A, interleukin 1B).
(Figure 4C), neutrophils (interleukin 8) (Figure 2E), B cells (receptor signaling) (Figure 2E), and T cells (interleukin 13, interleukin 17A) (Figure 4C). These data show that in colon and AOM/DSS tumors FOXO3 deficiency leads to an altered immune cell landscape and inflammatory microenvironment that could potentially support cancer progression.

**In Mouse Colon, Forkhead Box O3 Deficiency Activates Transcriptional Programs Associated With Inflammation, Tumorigenesis, and Bacterial Signaling**

Next, we determined loss of FOXO3-dependent transcripts that may influence inflammation and cancer. Initially, GSEA recognized a prevalent number of FOXO3 DE transcripts as being regulated by inflammatory nuclear factor kappa B (NFκB) and tumorigenic cMyc transcription factors (Figure 5A). Moreover, among FOXO3 KO DE transcripts that were shared with AOM/DSS tumors (Figure 2C), we selected 50 novel transcripts (Table 1) that could play a potential role in colon cancer. IPA also demonstrated numerous elevated DE transcripts with biological roles in inflammation and cancer progression (Figure 5B) including S100A8, Wnt ligands, and several matrix metalloproteinases (MMPs). Furthermore, the transcriptome of FOXO3 KO colon displayed activated signals specific for bacterial factor(s) recognition including Toll-like receptors TLR4, TLR7, TLR8, and their downstream transducer MYD88 (Figures 4C and 5B). In particular, significant up-regulation of TLR4 expression (2.5-fold) was validated by qPCR in FOXO3 KO colon (Figure 5C). Several of these TLRs, expressed in colonic cells and antigen presenting cells, are associated with increased susceptibility to developing intestinal inflammation and cancer.

**Altered Expression of Novel Integrin Subunit Alpha 2, ADAM Metallopeptidase With Thrombospondin Type 1 Motif 12, and ST8 Alpha-N-Acetyl-Neuraminide Alpha-2,8-Sialyltransferase 5 Transcripts in Mouse and Human Colon and Tumors**

Because our bioinformatics revealed FOXO3 deficiency altered transcripts that were also dysregulated in tumors,
we used molecular approaches to validate expression of select DE transcripts in FOXO3 KO colon and tumors (WT and KO). Among transcripts positively or negatively dependent on FOXO3, we selected those genes (significantly DE) with diverse functions and select abundances in colonic and non-colonic cells. Specifically, we validated ITGA2, a membrane and intracellular integrin family member highly expressed in the colon, ADAMTS12, an extracellular and intracellular metallopeptidase family with expression in colonic and non-colonic cells, and ST8SIA5, a sialyl-transferase involved in ganglioside synthesis, with low basal expression in the colon and possible localization to the Golgi. Quantitative PCR and immunohistostaining showed significantly increased expression of ITGA2 and ADAMTS12 as well as decreased ST8SIA5 in FOXO3 KO colon and tumors relative to WT (Figure 6) confirming RNAseq data. In mouse WT colon, ITGA2 protein was present in colonic cells, mostly localized in the membrane of proliferative cells of the crypt, whereas in KO colon and tumors, its overall levels were considerably augmented. Also, in mouse WT colon, ADAMTS12 protein was localized in colonic cells (intracellular and membrane) along the crypt, whereas in FOXO3 KO colon and tumors, it was elevated in colonic but more noticeably in non-colonic cells. ST8SIA5 was present at lower levels in colonic cells, more so in upper parts of crypt cells potentially within vacuoles as evident by punctate staining. In FOXO3 KO colon and tumors, the amount of ST8SIA5 was diminished (Figure 6). Furthermore, as a positive control, tissues were stained for Ki67, which demonstrated an increased number of proliferative cells in FOXO3 KO colon relative to WT (Figure 6B), confirming our previous finding of increased proliferation in response to
| Gene   | Gene name                                      | Colon FOXO3 KO | Tumor (AOM/DSS) |
|--------|-----------------------------------------------|----------------|-----------------|
| SGSM3  | Small G protein signaling modulator 3         | 595.078        | 91.142          |
| FAM103A1 | Family with sequence similarity 103, member A1 | 565.122        | 152.628         |
| ZBED6  | Zinc finger, BED type containing 6            | 106.973        | 61.437          |
| MCPT4  | Mast cell protease 4                          | 41.723         | 19.823          |
| CFD    | Complement factor D                           | 33.033         | 7.816           |
| ADIPOQ | Adiponectin, C1Q and collagen domain          | 30.559         | 10.799          |
| LEP    | Leptin                                        | 25.853         | 16.14           |
| CPA3   | Carboxypeptidase A3, mast cell                | 25.089         | 8.962           |
| ARFIP1 | ADP ribosylation factor interacting protein 1 | 20.479         | 3.18            |
| S100A8 | S100 calcium binding protein A8               | 15.034         | 792.785         |
| AMD1   | S-adenosylmethionine decarboxylase 1          | 14.958         | 2.282           |
| RMB12  | RNA binding protein 12                        | 12.773         | 11.412          |
| MOAP1  | Modulator of apoptosis 1                      | 12.399         | 4.448           |
| CHSY3  | Chondroitin sulfate synthase 3                | 10.147         | 4.858           |
| KLF12  | Kruppel like factor 12                        | 7.802          | 6.82            |
| WNT16  | Wnt family member 16                          | 6.814          | 37.196          |
| UPRT   | Uracil phosphoribosyltransferase              | 6.174          | 2.941           |
| LCOR   | Ligand dependent nuclear receptor Corepressor | 6.089          | 3.089           |
| SYNE3  | S-adenosylmethionine decarboxylase 1          | 5.891          | 1.515           |
| PAPLN  | Papulin, proteoglycan-like sulfated glycoprotein | 5.62          | 3.152           |
| CBL    | Cbl proto-oncogene                            | 5.582          | 2.108           |
| LMBRD2 | LMBR1 domain containing 2                     | 5.479          | 2.988           |
| LNPEP  | Leucyl/cysteinyI aminopeptidase               | 5.468          | 2.236           |
| NTSC1A | 5’-nucleotidase, cytosolic IA                | 5.194          | 3.413           |
| ATP7A  | ATPase, copper transporting alpha             | 5.098          | 3.102           |
| C CDC85C | Coiled-coil domain containing 8C              | 4.722          | 2.782           |
| PCOLCE2| Procollagen C-endopeptidase enhancer 2       | 4.847          | 1.806           |
| SLFN5  | Schlaen 5                                    | 4.763          | 3.99            |
| SAMD12 | Sterile alpha motif domain containing 12      | 4.647          | 5.439           |
| ITGA2  | Integrin alpha 2                             | 4.356          | 20.059          |
| EXPH5  | Exophillin 5                                 | 4.348          | 2.457           |
| PM20D2 | Peptidase M20 domain containing 2             | 4.105          | 6.56            |
| PTAR1  | Protein prenyltransferase alpha subunit repeat containing 1 | 4.006 | 2.109 |
| VPS13C | Vacuolar protein sorting 13C                 | 4              | 1.736           |
| ADAMTS12 | ADAM metalloproteinase with thrombospondin type 1 motif 12 | 3.927 | 16.032          |
| TCHH   | Trichohyalin                                 | 3.897          | 5.262           |
| XKRR4  | XK related 4                                 | 3.895          | 3.658           |
| MIA2   | Melanoma inhibitory activity 2               | 3.847          | 2.227           |
| PDPR   | Pyruvate dehydrogenase phosphatase regulatory subunit | 3.784 | 1.999 |
| PCDC5C | Protocadherin gamma subfamily C, 3           | 3.771          | 3.844           |
| IGF1P3 | Insulin-like growth factor binding protein 3  | 3.711          | 10.152          |
| STON2  | Stonin 2                                     | 3.646          | 1.98            |
| ADAMTS3 | ADAM metalloproteinase with thrombospondin type 1 motif 3 | 3.574 | 2.979          |
| ARSB   | Arylsulfatase B                              | 3.568          | 1.626           |
| TNKS   | Tankyrase                                    | 3.502          | 2.947           |
| SERPINA3 | Serpin family A member 3                    | 3.48           | 7.076           |
| SLC25A30 | Solute carrier family 25, member 30          | 3.436          | 4.609           |
| SNX29  | Sorting nexin 29                             | 3.356          | 1.737           |
| WDFY2  | WD repeat and FYVE domain containing 2       | 3.308          | 3.602           |
| LPAR5  | Lysophosphatidic acid receptor 5             | 3.295          | 2.073           |
## Table 1. Continued

| Gene       | Gene name                                                                 | Colon FOXO3 KO | Tumor (AOM/DSS) |
|------------|---------------------------------------------------------------------------|----------------|-----------------|
| LENEKP     | Lens epithelial protein                                                    | -85.425        | -69.786         |
| USP9Y      | Ubiquitin specific peptidase 9, y-linked                                   | -42.229        | -22.166         |
| DDX54      | DEAD box polypeptide 54                                                    | -21.688        | -2.797          |
| UGT1A4     | UDP glucuronosyltransferase 1 family, polypeptide A4                        | -21.403        | -14.754         |
| LIPF       | Lipase F                                                                   | -9.735         | -5.841          |
| RPGRIP1    | Retinitis pigmentosa GTPase regulator Interacting protein 1               | -5.034         | -3.058          |
| RPL41      | Ribosomal protein L41                                                      | -4.189         | -2.691          |
| CES3       | Carboxylesterase 3                                                         | -3.743         | -6.789          |
| RAB33A     | RAB33A, member RAS oncogene family                                        | -3.669         | -4.316          |
| RGS1       | Regulator of G-protein signaling 1                                         | -3.665         | -5.723          |
| NTAN1      | N-terminal Asn amidase                                                     | -3.566         | -2.115          |
| UGT1A1     | UDP glucuronosyltransferase 1 family, polypeptide A1                        | -3.531         | -2.425          |
| UGT2B17    | UDP glucuronosyltransferase family 2, member B17                           | -3.505         | -3.248          |
| MFSD9      | Major facilitator superfamily domain containing 9                         | -3.397         | -2.942          |
| SPDYA      | Speedy/RINGO cell cycle regulator family, member A                         | -3.128         | -1.815          |
| SLC17A1    | Solute carrier family 17, member 1                                        | -2.86          | -2.822          |
| CFAP52     | Cilia and flagella associated protein 52                                   | -2.763         | -1.652          |
| DPPA5      | Developmental pluripotency associated 5                                   | -2.698         | -3.306          |
| NR1I3      | Nuclear receptor subfamily 1 group I member 3                              | -2.674         | -6.541          |
| SERPINC1   | Serpin family C member 1                                                   | -2.57          | -1.717          |
| CDA        | Cytidine deaminase                                                         | -2.547         | -1.518          |
| TAT        | Tyrosine aminotransferase                                                  | -2.402         | -3.844          |
| NLRP9      | NLR family pyrin domain containing 9                                       | -2.339         | -5.906          |
| GDPD2      | Glycerophosphodiester phosphodiesterase domain containing 2               | -2.28          | -2.539          |
| NEK3       | NIMA related kinase 3                                                      | -2.235         | -3.583          |
| CCDC62     | Coiled-coil domain containing 62                                            | -2.234         | -3.062          |
| ST8SIA5    | ST8 aspha-N-acetyl-neuraminide alpha-2,8-sialytransferase 5                | -2.232         | -6.472          |
| CHKB       | Choline kinase beta                                                        | -2.219         | -2.888          |
| IL5RA      | Interleukin 5 receptor subunit alpha                                       | -2.218         | -2.015          |
| RPL10A     | Ribosomal protein L10A                                                     | -2.2           | -1.514          |
| RPS13      | Ribosomal protein s13                                                      | -2.191         | -1.329          |
| PIGH       | Phosphatidylinositol glycan anchor biosynthesis, class H                   | -2.159         | -2.072          |
| LINGO4     | Leucine rich repeat and Ig domain containing 4                             | -2.159         | -5.562          |
| CCDC152    | Coiled-coil domain containing 152                                          | -2.131         | -3.069          |
| RSRP1      | Arginine/serine rich protein 1                                             | -2.13          | -1.756          |
| ALS2CL     | Als2 C-terminal like                                                       | -2.081         | -1.219          |
| B3GAT2     | Beta-1,3-glucuronyltransferase 2                                           | -2.074         | -1.656          |
| Aph1c      | Aph1 homolog, gamma secretase subunit                                      | -2.059         | -3.541          |
| CYP2C44    | Cytochrome family 2, subfamily c, polypeptide 23                           | -2.049         | -5.493          |
| GAL        | Galanin                                                                    | -2.045         | -1.863          |
| SUN3       | Sad1 and UNC84 domain containing 3                                         | -2.044         | -2.582          |
| FTH1       | Ferritin heavy polypeptide 1                                               | -2.033         | -1.886          |
| PLSCR4     | Phospholipid scramblase 4                                                  | -2.028         | -3.39           |
| TCF7L2     | Transcription factor 7 like 2                                              | -2.015         | -2.63           |
| PNP        | Purine-nucleoside phosphorylase                                            | -2.008         | -2.019          |
| RHBDL1     | Rhomboid like 1                                                             | -1.997         | -2.056          |
| ARGLU1     | Arginine and glutamate rich 1                                              | -1.991         | -1.564          |
| GSDMC      | Gasdermin C                                                                | -1.987         | -5.246          |
| OOEP       | Oocyte expressed protein                                                   | -1.981         | -5.338          |
| AQP8       | Aquaporin 8                                                                 | -1.967         | -9.629          |

*Indicates colon cancer biomarker (FDR < 0.05, fold change >1.5), IPA.
Figure 6. Altered expression of ITGA2, ADAMTS12, and ST8SIA5 transcripts in mouse colon and tumors. (A) Altered levels of select, novel transcripts in FOXO3 KO colon and tumors was confirmed by qPCR (n = 3 per group from 2 independent experiments; **P < .05 *relative to WT colon, *relative to WT tumor; analysis of variance and Student-Newman-Keuls post-test). (B) Immunohistostainings of ITGA2, ADAMTS12, ST8SIA5, and Ki67 in colon and tumors of WT and FOXO3 KO mice. In WT and FOXO3 KO colon, gray boxes represent optical zoom images from the crypt base, midsection, and apical region as displayed as panels on the right. Insets in tumor panels (WT and FOXO3 KO) depict higher magnification of tumor and stromal sections (representative staining from colon and tumors of 3 mice from 2 independent immunohistostainings, scale bar 25 μm).
loss of FOXO3. These data demonstrate that in colon loss of FOXO3 leads to altered expression of ITGA2, ADAMTS12, and ST8SIA5 transcripts with potential roles in inflammation-mediated colon cancer progression.

**Human Inflammatory Bowel Disease and Colon Cancer Progression Are Associated With Altered Expression of Novel Integrin Subunit Alpha 2, ADAM Metallopeptidase With Thrombospondin Type 1 Motif 12, and ST8 Alpha-N-Acetyl-Neuraminide Alpha-2,8-Sialyltransferase 5 Transcripts**

We examined in human IBD and colon cancer patient cohorts whether altered ITGA2, ADAMTS12, and ST8SIA5 levels might play a role in their pathobiology. Similar to mouse inflammatory tumors, in IBD tissue (GSE4183) levels of both ITGA2 and ADAMTS12 transcripts were substantially increased, whereas ST8SIA5 was reduced (Figure 7A). In human colon cancer (TCGA), ITGA2, ADAMTS12, and ST8SIA5 expression co-occurred with established colon cancer biomarkers (data not shown), and their combined alterations including gene amplification, mutations, and mRNA/protein dysregulation were seen in 14% of colon cancer patients (Figure 7B). Moreover, analysis of human colon cancer transcriptomes (TCGA) indicated ITGA2 and ADAMTS12 levels were substantially increased, whereas expression of ST8SIA5 was considerably decreased compared with normal colon (Figure 7C; RSEM, P < .001). This trend of ITGA2, ADAMTS12, and ST8SIA5 expression was also found in other cancers such as esophagus, stomach, liver, lung, kidney, breast, and prostate (data not shown). Moreover, expression levels of these transcripts in human colon as shown by RNAseq (RSEM, Figure 7C) appear to be similar to levels observed in mouse tissues (Figure 6B), eg, high ITGA2, moderate ADAMTS12, and low ST8SIA5 expression. Ultimately, in human colon cancer, increased ITGA2 and ADAMTS12 as well as decreased ST8SIA5 were associated with poor patient survival (Figure 7D). These data indicate that these novel transcripts dependent on loss of FOXO3 have altered expression in human IBD and colon cancer possibly implicating their role in progression of both pathobiologies.

**In Human Colon Cancer Cells Forkhead Box O3 Silencing Mediates Increased Integrin Subunit Alpha 2 Levels Leading to Increased Proliferation**

Next, we assessed whether expression of these novel transcripts occurred in colon cancer cells, was FOXO3-dependent, and had any possible role in cancer progression. Emerging studies showed that although ITGA2 and ADAMTS12 are found in fibroblasts, their expression and potential roles in colonic cells are not examined. Thus, we generated human colon cancer HCT116 cells with FOXO3-specific knockdown using shRNA (shFOXO3) under inducible doxycycline (dox)-inducible promoter. Among several stable transfected clones, we selected those that after dox-treatment showed reduction in endogenous FOXO3 (mRNA and protein) levels (50% ± 4%) (Figure 8A and C). In HCT116 cells, with or without shFOXO3, levels of ADAMTS12 and ST8SIA5 were insignificant, as assessed by qPCR and immunoblot (data not shown), most likely because of low baseline expression (ST8SIA5) or high methylation status (ADAMTS12) of these genes in colon cancer cells. However, ITGA2, expressed in colon cancer HCT116 cells, was increased more than 2.5-fold in response to 50% FOXO3 knockdown (Figure 8B and C). Moreover, in human colon cancer HCT116 cells silencing of ITGA2 (siRNA) led to significant reduction in cell proliferation (47% ± 2%), indicating a potential role for this gene in colon cancer cell growth (Figure 8D). Although further study is required to determine whether increased ITGA2 expression is directly or indirectly dependent on loss of FOXO3, these findings demonstrate colon cancer cell specific ITGA2 regulation that could facilitate elevated cancer cell growth.

**Discussion**

Colon cancer increased risk, progression, and resistance to chemotherapy is linked to an inflammatory microenvironment; however, the mechanisms involved in inflammation promoted tumor growth are not fully understood. Here, in a mouse model of inflammation-mediated colon cancer, we identified alterations driven by loss of FOXO3 within the immune cell landscape, molecular pathways, and transcripts leading to tumor growth. In mouse colon and tumors, we validated differential expression of novel transcripts including ITGA2, ADAMTS12, and ST8SIA5 in response to FOXO3 deficiency. Their expression was similarly altered in human IBD and cancer tissues and associated with poor survival in colon cancer patients. Also, in human colon cancer cells, increased ITGA2 expression, mediated by loss of FOXO3 function, was important for cell growth. These findings provide an opportunity to pursue new mechanisms, biomarkers, and prospective targets for treatment of inflammation-mediated colon cancer.

In mouse colon, deficiency in FOXO3 led to increased tumor incidence and size in the AOM/DSS model. Similar to human inflammatory colon cancer samples, mouse colon deficient in FOXO3 exhibited a strong presence of neutrophils, macrophages, B and T cells, and decreased NK cells. Also, FOXO3-deficient colon and tumors had notably elevated B cells relative to WT. We speculate this effect could be a direct consequence of FOXO3 deficiency in B cells leading to their proliferation and enhanced activity or occurring as a result of a B-cell response to commensal bacteria because FOXO3 deficiency also activated bacterial TLR signaling. Whether this immune profile is active or inactive and possesses pro- or anti-tumor functions remains unclear; however, emerging findings in human and mouse models have revealed that individually macrophages, neutrophils, T cells, and NK cells play important roles in colon cancer progression. For example, Jobin et al demonstrated that individuals with lower NK cell activity in blood have substantially higher risk of developing colon cancer. Also, in mouse colon, macrophages polarized by commensal bacteria have been shown to stimulate inflammation and...
B
Altered in 89 (14%) of 631 sequenced cases/patients (636 total)

- ITGA2: 4%
- ADAMTS12: 8%
- ST8SIA5: 4%

Genetic Alteration
- Missense mutation
- Truncating mutation
- Amplification
- Deep Deletion
- mRNA upregulation
- mRNA downregulation
- No alterations

C

D
GSE17536
Survival Measure - Overall Survival
Combined Gene Expression - ADAMTS12, ITGA2
Cohort Divided at Median of Gene Expression

GSE16125
Survival Measure - Overall Survival
ST8SIA5 Gene Expression
Cohort Divided at Median of Gene Expression
cancer progression. It has also been demonstrated that depletion of neutrophils with Ly6G antibodies ameliorates tumor number and size, and together, molecular crosstalk between macrophages and neutrophils could promote infiltration of T cells. In addition to approved immunotherapy for MSI colon cancer that stimulates T-cell anti-tumor function, we speculate that determining the tumor functional roles of the FOXO3-dependent immune profile could lead to its targeting for more effective immunotherapeutic treatment regimens.

Functional deficiency of FOXO3 in mouse colon led to pathway activation associated with inflammatory NFkB and tumorigenic cMyc transcriptional programs as well as bacterial TLR signaling. Although activity of these transcription factors is linked to FOXO3 function, the contribution of NFkB and cMyc in individual cell types in inflammation-mediated colon cancer needs to be further examined. We found increased levels of transcripts associated with inflammation and cancer, which might be directly regulated by FOXO3 or indirectly by NFkB and cMyc. Moreover, in FOXO3 KO colon, increased TLRs (level and activity) could lead to enhanced sensitivity to luminal commensal bacteria. Because bacterial products stimulate inflammation in part through loss of FOXO3 function, our findings suggest a possible feedback between FOXO3 function and TLR signaling that may also drive inflammatory tumor growth.

Together, loss of colonic FOXO3 might simultaneously orchestrate downstream signaling that could promote

---

**Figure 7.** (See previous page). Expression of ITGA2, ADAMTS12, and ST8SIA5 transcripts across human IBD and colon cancer. (A) In human IBD tissue samples, levels of ITGA2, ADAMTS12, and ST8SIA5 were significantly altered relative to normal control (GSE4183, n = 23 patient samples, Agilent Microarray Probe ID: ITGA2 (22734_at), ADAMTS12 (226997_at), ST8SIA5 (217514_at); *P < .05 compared with healthy control, Student t test). (B) OncoPrint alteration summary of ADAMTS12, ITGA2, and ST8SIA5 in human colon cancer (TCGA) (cbioportal.org, *P < .05). (C and D) mRNA expression of select, novel transcripts ITGA2, ADAMTS12, and ST8SIA5 were significantly altered in human colon cancer compared with matched control tissue (TCGA) (TIMER, ***P < .001 compared with normal tissue) and were associated with poor patient survival as measured by KM estimate (PROGgeneV2) (*P < .05).

**Figure 8.** In human colon cancer HCT116 cells FOXO3 silencing leads to increased ITGA2 levels that promote growth. (A) Human colon cancer HCT116 clones with (dox)-inducible (2 µg/mL, 48 hours) FOXO3-specific shRNA (shFOXO3) were assessed for reduced FOXO3 mRNA levels (n = 4 from 2 independent experiments and clones; **#P < .05, *compared with control (shCon) (-dox), #compared with shFOXO3 (-dox); analysis of variance and Student-Newman-Keuls post-test). (B) Increased ITGA2 expression in response to FOXO3 knockdown (shFOXO3) in colon cancer cells was determined by qPCR (n = 4 from 2 independent experiments and clones; **#P < .05, *compared with shCon (-dox), #compared with shFOXO3 (-dox); analysis of variance and Student-Newman-Keuls post-test). (C) Immunoblot of elevated ITGA2 and reduced FOXO3 protein levels in shFOXO3 colon cancer cells (n = 4 from 2 independent experiments and clones; **#P < .05, *compared with shCon (-dox), #compared with shFOXO3 (-dox); analysis of variance and Student-Newman-Keuls post-test). (D) MTS proliferation assay of colon cancer cells left untreated (control, Con) or transfected with non-specific scramble (NS) siRNA or ITGA2 specific siRNA (n = 8 per condition from 2 independent experiments; **#P < .05, *compared with Con, #compared with NS Con; analysis of variance and Student-Newman-Keuls post-test).
increased sensitivity to commensal bacteria and inflammation leading to cancer initiation and progression.

We identified in mouse colon a substantial number of novel transcripts that might be directly or indirectly altered because of FOXO3 functional deficiency or consequently because of activated inflammatory-tumorigenic programs including ITGA2, ADAMTS12, and ST8SIA5. In human colon cancer tissues, increased ADAMTS12 expression is found predominantly in fibroblasts, and although in various human colon cancer cell lines there is lack of ADAMTS12 expression because of methylation, its expression is recovered after co-culture with fibroblasts. Our findings demonstrate that ADAMTS12 levels, while negligibly present in human colon cancer cells, were significantly increased (transcripts and protein) in mouse colonic cells of FOXO3 KO colon and tumors, as well as in infiltrated non-colon cells. Furthermore, in mouse colon, ST8SIA5 protein appears to localize in select colonic cells. Although in human colon cancer cells ST8SIA5 expression level was negligible, its further decrease in human colon cancer appeared to be critical for poor patient survival. Moreover, emerging findings have revealed in IBD patients that genome-wide variants in ST8SIA5 are associated with response to select therapy; in addition, an ST8SIA5 family member (ST8SIA1) has been recently used in immunotherapeutic vaccine delivery to stimulate NK cell activity against tumor growth. Thus, although ST8SIA5 levels might be low in colon, recovery of its levels/function might have potential therapeutic benefits in IBD and colon cancer. Moreover, ITGA2 abundance was found not only in mouse colonic cells and tumors but also in human colon cancer cells and was critical for cell growth. Increased ITGA2 has recently been implicated in fibroblast-driven inflammatory rheumatoid arthritis, resistance of gastric cancer cells to apoptosis, and human colon cancer metastasis. We speculate that in colon elevated ITGA2 exerts multiple functions in colonic and non-colonic cells to facilitate inflammation-mediated cancer pathobiology. Moreover, because we found that partial reduction in FOXP3 levels in human colon cancer cells led to significantly increased ITGA2 expression, we speculate that in human colon SNPs in the FOXO3 gene might have significant implications in driving gene expression involved in inflammatory and cancer progression. In addition, whether these novel transcripts are directly or indirectly regulated by FOXO3 is unclear; they could act as novel functional regulators in inflammation-mediated colon cancer progression.

In conclusion, FOXO3 deficiency in a mouse model of inflammation-mediated colon cancer increases colonic tumor burden. Moreover, loss of FOXO3 also leads to elevated intracellular lipids, an emerging aspect of metabolic reprogramming associated with inflammation and colon cancer, suggesting FOXO3’s metabolic function may also be involved in these disease processes. These findings underline novel FOXO3-dependent regulators that could serve as biomarkers and prospective new targets for treatment of colon cancer. Overall, understanding the immune landscape and molecular pathways of inflammation-mediated colon cancer highlights a future direction for precision diagnostics and personalized treatments.

References

1. Colotta F, Allavena P, Sica A, Garlanda C, Mantovani A. Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis 2009; 30:1073–1081.
2. Pietrzyk L, Torres A, Maciejewski R, Torres K. Obesity and obese-related chronic low-grade inflammation in promotion of colorectal cancer development. Asian Pac J Cancer Prev 2015;16:4161–4168.
3. Elina E, Nowarski R, Thaiss CA, Hu B, Jin C, Flavell RA. Inflammation-induced cancer: crosstalk between tumours, immune cells and microorganisms. Nat Rev Cancer 2013;13:759–771.
4. Itzkowitz SH, Yio X. Inflammation and cancer IV: colorectal cancer in inflammatory bowel disease—the role of inflammation. Am J Physiol Gastrointest Liver Physiol 2004;287:G7–G17.
5. Rubin DC, Shaker A, Levin MS. Chronic intestinal inflammation: inflammatory bowel disease and colitis-associated colon cancer. Front Immunol 2012;3:107.
6. Fridman WH, Pages F, Sautes-Fridman C, Galon G. The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer 2012;12:298–306.
7. Biggs WH 3rd, Cavenee WK, Arden KC. Identification and characterization of members of the FKHR (FOX O) subclass of winged-helix transcription factors in the mouse. Mamm Genome 2001;12:416–425.
8. Coomans de Brachene A, Demoulin JB. FOXO transcription factors in cancer development and therapy. Cell Mol Life Sci 2016;73:1159–1172.
9. Ttofova Z, Gilliland DG. FoxO transcription factors and stem cell homeostasis: insights from the hematopoietic system. Cell Stem Cell 2007;1:140–152.
10. Peng SL. Foxo in the immune system. Oncogene 2008; 27:2337–2344.
11. Lin L, Hron JD, Peng SL. Regulation of NF-kappaB, Th activation, and autoinflammation by the forkhead transcription factor Foxo3a. Immunity 2004;21:203–213.
12. Lee JC, Espeli M, Anderson CA, Linterman MA, Pocock JM, Williams NJ, Roberts R, Viatte S, Fu B, Peshu N, Hien TT, Phu NH, Wesley E, Edwards C, Ahmad T, Mansfield JC, Geary R, Dunstan S, Williams TN, Barton A, Vinuesa CG, UK IBD Genetics Consortium Parkes M, Lyons PA, Smith K. Human SNP links differential outcomes in inflammatory and infectious disease to a FOXO3-regulated pathway. Cell 2013;155:57–69.
13. Bullock MD, Bruce A, Sreekumar R, Curtis N, Cheung T, Reading I, Primrose JN, Ottensmeier C, Packham GK, Thomas G, Mirnezami AH. FOXO3 expression during colorectal cancer progression: biomarker potential reflects a tumour suppressor role. Br J Cancer 2013; 109:387–394.
14. Snoeks L, Weber CR, Wasland K, Turner JR, Vaidner C, Qi W, Savkovic SD. Tumor suppressor FOXO3
participates in the regulation of intestinal inflammation. Lab Invest 2009;89:1053–1062.

15. Qi W, Weber CR, Wasland K, Wasland K, Roy H, Wali R, Joshi S, Savkovic SD. Tumor suppressor FOXO3 mediates signals from the EGF receptor to regulate proliferation of colonic cells. Am J Physiol Gastrointest Liver Physiol 2011;300:G264–G272.

16. Greten FR, Eckmann L, Greten TF, Park JM, Li ZW, Egan LJ, Kagnoff MF, Karin M. IKKbeta links inflammation and tumorgenesis in a mouse model of colitis-associated cancer. Cell 2004;118:285–296.

17. Fellmann C, Hoffmann T, Sridhar V, Hopfgartner B, Muhar M, Roth M, Lai DY, Barbosa IA, Kwon JS, Guan Y, Sinha N, Zuber J. An optimized microRNA backbone for effective single-copy RNAi. Cell Rep 2013;5:1704–1713.

18. Snoeks L, Weber CR, Turner JR, Bhattacharyya M, Wasland K, Savkovic SD. Tumor suppressor Foxo3a is involved in the regulation of lipopolysaccharide-induced interleukin-8 in intestinal HT-29 cells. Infect Immun 2008;76:4677–4685.

19. Penrose HM, Heller S, Cable C, Nakhoul H, Baddoo M, Flemington E, Crawford SE, Savkovic SD. High-fat diet induced leptin and Wnt expression: RNA-sequencing and pathway analysis of mouse colonic tissue and tumors. Carcinogenesis 2017;38:302–311.

20. Heller S, Penrose HM, Cable C, Biswas D, Nakhoul H, Baddoo M, Flemington E, Crawford SE, Savkovic SD. Reduced mitochondrial activity in colonocytes facilitates AMPKalpha2-dependent inflammation. FASEB J 2017;31:2013–2025.

21. Kerr TA, Ciorba MA, Matsumoto H, Davis VR, Luo J, Kennedy S, Xie Y, Shaker A, Dieckgraefe BK, Davidson NO. Dextran sodium sulfate inhibition of real-time polymerase chain reaction amplification: a poly-A purification solution. Inflamm Bowel Dis 2012;18:344–348.

22. Barrett T, Wilhite SE, Ledoux P, Evangelista C, Kim IF, Tomashevsky M, Marshall KA, Phillippy KH, Sherman PM, Holko M, Yefanov A, Lee H, Zhang N, Robertson CL, Serova N, Davis S, Soboleva A. NCBI GEO: archive for functional genomics data sets—update. Nucleic Acids Res 2013;41:D991–D995.

23. Cancer Genome Atlas Network. Comprehensive molecular characterization of human colon and rectal cancer. Nature 2012;487:330–337.

24. Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, Sun Y, Jacobsen A, Sinha R, Larsson E, Cerami E, Sander C, Schultz N. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal 2013;6:p11.

25. Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, Jacobsen A, Byrne CJ, Heuer ML, Larsson E, Antipin Y, Reva B, Goldberg AP, Sander C, Schultz N. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov 2012;2:401–404.

26. Li B, Dewey CN. RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome. BMC Bioinformatics 2011;12:323–339.

27. Newman AM, Liu CL, Green MR, Gentles AJ, Feng W, Xu Y, Hoang CD, Diehn M, Alizadeh AA. Robust enumeration of cell subsets from tissue expression profiles. Nat Methods 2015;12:453–457.

28. Li B, Severson E, Pignon JC, Zhao H, Li T, Novak J, Jiang P, Shen H, Aster JC, Rodrig S, Signoretti S, Liu JS, Liu XS. Comprehensive analyses of tumor immunity: implications for cancer immunotherapy. Genome Biol 2016;17:174.

29. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES, Mesirov JP. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A 2005;102:15545–15550.

30. Burgering BM, Kops GJ. Cell cycle and death control: long live Forkheads. Trends Biochem Sci 2002;27:352–360.

31. Samuels Y, Ericson K. Oncogenic PI3K and its role in cancer. Curr Opin Oncol 2006;18:77–82.

32. Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell 2010;140:883–899.

33. Kim HJ, Kang HJ, Lee H, Loee ST, Yu MH, Kim H, Lee C. Identification of S100A8 and S100A9 as serological markers for colorectal cancer. J Proteome Res 2009;8:1368–1379.

34. Cho KH, Baek S, Sung MH. Wnt pathway mutations selected by optimal beta-catenin signaling for tumorigenisis. FEBS Lett 2006;580:3665–3670.

35. Storz P, Doppler H, Copland JA, Simpson KJ, Toker A. FOXO3a promotes tumor cell invasion through the induction of matrix metalloproteinases. Mol Cell Biol 2009;29:4906–4917.

36. Fukata M, Abreu MT. TLR4 signalling in the intestine in health and disease. Biochem Soc Trans 2007;35:1473–1478.

37. Sanchez-Munoz F, Fonseca-Camarillo G, Villeda-Ramirez MA, Miranda-Perez E, Mendivil EJ, Barreto-Zuniga R, Uribe M, Bojalil R, Dominguez-Lopez A, Yamamoto-Furusho JK. Transcript levels of Toll-like receptors 5, 8 and 9 correlate with inflammatory activity in ulcerative colitis. BMC Gastroenterol 2011;11:138.

38. Kapp TG, Rechenmacher F, Sobahi TR, Kessier H. Integrin modulators: a patent review. Expert Opin Ther Pat 2013;23:1273–1295.

39. Wei J, Richbourgh B, Jia T, Liu C. ADAMTS-12: a multifaceted metalloproteinase in arthritis and inflammation. Mediators Inflamm 2014;2014:649718.

40. Wang XQ, Sun P, Paller AS. Ganglioside modulation of Toll-like receptors 5, 8 and 9 correlates with inflammatory activity in ulcerative colitis. BMC Bioinformatics 2009;10:278.
42. Peters MA, Wendholt D, Strietholt S, Frank S, Pundt N, Korb-Pap A, Joosten LA, van den Berg WB, Kollias G, Eckes B, Pap T. The loss of alpha2beta1 integrin suppresses joint inflammation and cartilage destruction in mouse models of rheumatoid arthritis. Arthritis Rheum 2012;64:1359–1368.

43. Jobin G, Rodriguez-Suarez R, Betito K. Association between natural killer cell activity and colorectal cancer in high-risk subjects undergoing colonoscopy. Gastroenterology 2017;153:980–987.

44. Yang Y, Wang X, Huycke T, Moore DR, Lightfoot SA, Huycke MM. Colon macrophages polarized by commensal bacteria cause colitis and cancer through the bystander effect. Transl Oncol 2013;6:596–606.

45. Shang K, Bai YP, Wang C, Wang Z, Gu HY, Du X, Zhou XY, Zheng CL, Chi YY, Mukaida N, Li YY. Crucial involvement of tumor-associated neutrophils in the regulation of chronic colitis-associated carcinogenesis in mice. PLoS One 2012;7:e51848.

46. Rahat MA, Coffelt SB, Granot Z, Muthana M, Amedei A. Macrophages and neutrophils: regulation of the inflammatory microenvironment in autoimmunity and cancer. Mediators Inflamm 2016;2016:5894347.

47. Boland PM, Ma WW. Immunotherapy for colorectal cancer. Cancers (Basel) 2017;9.

48. Delpuech O, Griffiths B, East P, Essafi A, Lam EW, Burgner, Downard J, Schulze A. Induction of Mxi1-SR alpha by FOXO3a contributes to repression of Myc-dependent gene expression. Mol Cell Biol 2007;27:4917–4930.

49. Moran CJ, Huang H, Rivas M, Kaplan JL, Daly MJ, Winter HS. Genetic variants in cellular transport do not affect mesalamine response in ulcerative colitis. PLoS One 2018;13:e0192806.

50. Eby JM, Barse L, Henning SW, Rabelink MJ, Klarquist J, Gilbert ER, Hammer AM, Fernandez MF, Yung N, Khan S, Miller HG, Kessler ER, Garrett-Mayer E, Dilling DF, Hoeben RC, Le Poole IC. Alpha-N-acetyllneuraminide alpha-2,8-sialyltransferase 1 can support immune responses toward tumors overexpressing ganglioside D3 in mice. Cancer Immunol Immunother 2017;66:63–75.

51. Chuang YC, Wu HY, Lin YL, Tzou SC, Chuang CH, Jian TY, Chen PR, Chang YC, Lin CH, Huang TH, Wang CC, Chan YL, Liao KW. Blockade of ITGA2 induces apoptosis and inhibits cell migration in gastric cancer. Biol Proced Online 2018;20:10.

52. Yang Q, Bavi P, Wang JY, Roehrk MH. Immuno-proteomic discovery of tumor tissue autoantigens identifies olfactomedin 4, CD11b, and integrin alpha-2 as markers of colorectal cancer with liver metastases. J Proteomics 2017;168:53–65.

53. Qi W, Fitchev PS, Cornwell ML, Greenberg J, Cabe M, Weber CR, Roy HK, Crawford SE, Savkovic SD. FOXO3 growth inhibition of colonic cells is dependent on intra-epithelial lipid droplet density. J Biol Chem 2013;288:16274–16281.

54. Cotte AK, Aires V, Fredon M, Limagne E, Derangere V, Thibaudin M, Humblin E, Scaglariini A, de Barros JP, Hillon P, Ghiringhelli F, Delmas D. Lysophosphatidylcholine acyltransferase 2-mediated lipid droplet production supports colorectal cancer chemoresistance. Nat Commun 2018;9:322.